Sitagliptin: A DPP-4 Inhibitor for Type 2 Diabetes

What is Sitagliptin?

Sitagliptin is an oral diabetes medication that belongs to a class of drugs called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). It is primarily used to help control blood sugar levels in adults with type 2 diabetes mellitus. This medication works by enhancing the body’s natural ability to regulate glucose levels, particularly after meals.

Uses

Sitagliptin has several approved medical uses for managing type 2 diabetes:

• Type 2 diabetes management: As a first-line or add-on therapy to help lower blood glucose levels when diet and exercise alone are insufficient
• Combination therapy: Used alongside other diabetes medications such as metformin, sulfonylureas, or insulin to improve glycemic control
• Monotherapy: Used as a single medication for patients who cannot tolerate metformin or when metformin is contraindicated
• HbA1c reduction: Helps reduce long-term blood sugar markers (hemoglobin A1c) to target levels recommended by diabetes guidelines
• Postprandial glucose control: Particularly effective at reducing blood sugar spikes that occur after eating meals

How it works

Sitagliptin works by blocking the DPP-4 enzyme, which normally breaks down incretin hormones like GLP-1 and GIP. By inhibiting this enzyme, sitagliptin increases the levels of these beneficial hormones, which stimulate insulin release when blood sugar is elevated and reduce glucagon production from the liver. This dual action helps maintain better blood glucose balance throughout the day, especially after meals.

Side effects

Common side effects include:

Submit Your Paper

• Upper respiratory tract infections
• Headache
• Nasopharyngitis (stuffy or runny nose)
• Nausea
• Diarrhea
• Constipation
• Joint pain (arthralgia)
• Dizziness

Serious side effects to watch for:

• Severe joint pain that may be disabling
• Pancreatitis (severe abdominal pain that may radiate to the back)
• Serious allergic reactions including skin reactions and swelling
• Heart failure symptoms (shortness of breath, swelling in legs or feet)
• Severe hypoglycemia when used with insulin or sulfonylureas

Warnings and precautions

• Kidney function: Dosage adjustment is required for patients with moderate to severe kidney impairment, as sitagliptin is primarily eliminated through the kidneys
• Pancreatitis risk: Patients should be monitored for signs of pancreatitis, and the medication should be discontinued if pancreatitis is suspected
• Heart failure: Use with caution in patients with a history of heart failure, as DPP-4 inhibitors may increase the risk of heart failure hospitalization
• Pregnancy and breastfeeding: Limited data available; should only be used if potential benefits justify potential risks to the fetus or nursing infant
• Hypoglycemia: While sitagliptin alone rarely causes low blood sugar, risk increases when combined with insulin or sulfonylureas

Interactions

• Insulin and sulfonylureas: May increase risk of hypoglycemia; dosage adjustments of these medications may be necessary
• Digoxin: Sitagliptin may slightly increase digoxin levels, requiring monitoring of digoxin concentrations
• Warfarin: May affect anticoagulation; monitor INR more frequently when starting or stopping sitagliptin
• ACE inhibitors: Potential for increased risk of angioedema, though rare
• Diuretics: May affect kidney function when used together; monitor kidney function regularly
• St. John’s Wort: May reduce sitagliptin effectiveness by increasing its metabolism
• Corticosteroids: May counteract glucose-lowering effects of sitagliptin
• Beta-blockers: May mask symptoms of hypoglycemia

Check interactions with the GMJ Interaction Checker

Dosage

The typical adult dosage of sitagliptin is 100 mg taken orally once daily, with or without food. For patients with moderate kidney impairment (creatinine clearance 30-50 mL/min), the dose should be reduced to 50 mg once daily. For those with severe kidney impairment (creatinine clearance less than 30 mL/min) or end-stage renal disease requiring dialysis, the dose should be reduced to 25 mg once daily. All dosage decisions should be individualized and determined by a healthcare provider based on kidney function, other medications, and overall health status.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).